Navigation Links
Nucletron Announces Oncentra(R) Brachy* Treatment Planning Solution for Multimodality Environment
Date:4/28/2008

VEENENDAAL, The Netherlands, April 28 /PRNewswire/ --

- New Anatomy-Based Solution for HDR/PDR Brachytherapy Represents the Next Generation in DICOM-Compatible, Integrated Cancer Treatment Planning

Nucletron, a knowledge-based leader in radiation oncology, today announced the introduction of Oncentra(R) Brachy*, a comprehensive volume-based treatment planning system to optimize cancer treatment planning with brachytherapy. Oncentra Brachy, the world's first fully DICOM-compatible treatment planning system, features state-of-the-art optimization algorithms to ensure efficient treatment. The new solution provides excellent 3D contouring and margining tools to identify Regions of Interests (ROIs) on CT or in a multimodality imaging environments using image registration for CT, MR and PET data.

Oncentra Brachy provides many benefits to clinicians allowing for faster and easier creation of treatment plans, ranging from simple to complex, in user-defined workspaces that allow for adaptation to specific clinical workflows. Real-time information-sharing provides immediate access for the entire medical team and facilitates the exchange of treatment plans over vast distances with decentralized planning capabilities. Physicians are able to evaluate and authorize treatment plans remotely.

"The release of Oncentra Brachy marks the first of some new and exciting treatment planning innovations forthcoming from Nucletron," said Jeroen Cammeraat, chief operating officer of Nucletron. "We have set a new benchmark in technological achievement with Oncentra Brachy that represents the future of brachytherapy treatment planning. We have worked with our clinical partners to develop a state-of-the art solution that includes many sophisticated and powerful new tools to improve patient care."

"Oncentra Brachy opens new possibilities to explore new treatment techniques for brachytherapy planning that could not be considered before," according to the radiation oncology department of the Academic Medical Center (AMC) in Amsterdam. "As reconstruction and planning on MR data becomes reality, the user-friendliness of the system provides clinicians and physicists all the flexibility they need. We are able to create optimal and accurate plans to yield better treatment for our patients."

Oncentra Brachy is a part of fully integrated solution for brachytherapy treatment of a wide variety of cancers, giving medical professionals the most advanced systems to optimally treat patients using brachytherapy.

"As one of the original gamma testing sites for Oncentra Brachy, I am very pleased with the efficient and flexible tools of this new treatment planning system from Nucletron," said I-Chow Hsu, M.D., University of California San Francisco. "After testing the system thoroughly, we are planning to use Oncentra Brachy exclusively in our center."

Nucletron will have Oncentra Brachy on display at the 2008 World Congress of Brachytherapy in Boston, MA , May 4-6 , Booth # 120.

* Regulatory clearance in North America is pending.

About Nucletron

Nucletron is a knowledge-based leader in Radiation Oncology, working with clinical teams to realize innovative solutions that improve patient care. Nucletron strives to offer the best possible choice of radiation modalities through integrated products, software and services. Critical to the Nucletron philosophy is the establishment of close working relationships with individual clinical teams - reconfiguring traditional boundaries between customer and solution provider. Many Nucletron employees have clinical experience delivering oncology care, providing an in-depth understanding of the complex needs of clinicians. For more information, visit http://www.nucletron.com.


'/>"/>
SOURCE Nucletron B V
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate
2. Alfacell Announces Retirement of Chief Executive Officer
3. Aida Pharmaceuticals, Inc. Announces Update on Progress of Rh-Apo2L Testing
4. Exelixis Announces May 6 Webcast of Its First Quarter 2008 Financial Results and Business Update Conference Call
5. ATS Medical Announces First Quarter 2008 Earnings Release Date and Conference Call
6. Dialysis Corporation of America Announces First Quarter 2008 Earnings Release Date
7. IDEXX Laboratories Announces First Quarter Results
8. Kosan Announces May 1, 2008 Conference Call and Webcast of First Quarter 2008 Financial Results
9. Exelixis Announces April 30 Webcast of Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
10. ETEX Announces Supply Agreement with AlloSource
11. Wyeth Chairman Robert Essner Announces June 27 Retirement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Regular discussions on a range of subjects ... the two entities said Poloz. Speaking at a ... , he pointed to the country,s inflation target, which ... "In certain areas ... have common economic goals, why not sit down and address ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal ... Their findings are the subject of a new article on the Surviving Mesothelioma website. ... the blood, lung fluid or tissue of mesothelioma patients that can help point doctors ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... , June 23, 2016 Houston ... with the Cy-Fair Sports Association to serve as ... the agreement, Houston Methodist Willowbrook will provide sponsorship ... and connectivity with association coaches, volunteers, athletes and ... with the Cy-Fair Sports Association and to bring ...
Breaking Biology Technology:
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
(Date:3/31/2016)... RATON, Florida , March 31, 2016 ... LEGX ) ("LegacyXChange" or the "Company") ... for potential users of its soon to be launched ... video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide ... the use of DNA technology to an industry that ...
Breaking Biology News(10 mins):